Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - venlafaxine hydrochloride - prolonged-release capsule, hard - 75 milligram(s) - other antidepressants; venlafaxine

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - venlafaxine hydrochloride - prolonged-release capsule, hard - 150 milligram(s) - other antidepressants; venlafaxine

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - meropenem trihydrate - pdr for soln inj/inf - 500 milligram - carbapenems - antibacterials for systemic use, carbapenems. - used for the treatment of the following infections in adults and children over 3 months of age:
pneumonia, including community acquired pneumonia and nosocomial pneumonia;
broncho-pulmonary infections in cystic fibrosis;
complicated urinary tract infections;
complicated intra-abdominal infections;
intra- and post-partum infections;
complicated skin and soft tissue infections;
acute bacterial meningitis.

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - meropenem trihydrate - pdr for soln inj/inf - 1 grams - carbapenems - antibacterials for systemic use, carbapenems - it is indicated for the treatment of the following infections in adults and children over 3 months of age :
pneumonia, including community acquired pneumonia and nosocomial pneumonia.
broncho-pulmonary infections in cystic fibrosis.
complicated urinary tract infections-
complicated intra-abdominal infections
intra- and post-partum infections.
complicated skin and soft tissue infections.
acute bacterial meningitis

European Union - English - EMA (European Medicines Agency)

pharmathen s.a. - ibandronic acid - hypercalcemia; fractures, bone; neoplasm metastasis; breast neoplasms - drugs for treatment of bone diseases - concentrate for solution for infusion prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. treatment of tumour-induced hypercalcaemia with or without metastases. film-coated tablets prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.,

European Union - English - EMA (European Medicines Agency)

pharmathen s.a. - levetiracetam - epilepsy - antiepileptics, - matever is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.matever is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.